## Phylogeny  
- Member of the NIMA-related kinase (NEK) family comprising eleven human paralogs (NEK1–NEK11) (dana2022nek2kinasesignaling pages 1-2).  
- Catalytic domain shares ~42-44 % identity with the Aspergillus nidulans mitotic regulator NIMA, making NEK2 the closest human homolog of the founding fungal kinase (fry2002thenek2protein pages 1-3, dana2022nek2kinasesignaling pages 1-2).  
- Documented orthologs include Pfnek-1 from Plasmodium falciparum, underscoring conservation of NEK-type cell-cycle kinases in apicomplexan parasites (dana2022nek2kinasesignaling pages 13-14).  
- NEK kinases localise to microtubule-organising centres across eukaryotes, reflecting an evolutionarily conserved role in centrosome regulation (fry2017mitoticregulationby pages 1-2).  

## Reaction Catalyzed  
ATP + protein-Ser/Thr → ADP + protein-O-phospho-Ser/Thr (dana2022nek2kinasesignaling pages 1-2).  

## Cofactor Requirements  
Requires Mg²⁺ or Mn²⁺ for catalytic activity (dana2022nek2kinasesignaling pages 28-29).  

## Substrate Specificity  
- Prefers Ser/Thr residues in basic sequence contexts (fry2002thenek2protein pages 1-3).  
- Experimentally confirmed substrates:  
  • CEP250/C-Nap1 and CROCC/Rootletin (dana2022nek2kinasesignaling pages 2-4, dana2022nek2kinasesignaling pages 28-29).  
  • CEP68 (dana2022nek2kinasesignaling pages 28-29).  
  • NDC80/Hec1 (dana2022nek2kinasesignaling pages 13-14).  
  • CDC20 and MAD2L1 (dana2022nek2kinasesignaling pages 28-29).  
  • PP1 catalytic subunit Thr320 (dana2022nek2kinasesignaling pages 6-7).  
  • NPM1 Ser70/Ser88 (dana2022nek2kinasesignaling pages 6-7, dana2022nek2kinasesignaling pages 7-9).  
  • β-Catenin, Dishevelled and TRF1 (dana2022nek2kinasesignaling pages 7-9).  
  • SGO1 and NECAB3 (dana2022nek2kinasesignaling pages 6-7).  

## Structure  
- 445-aa protein with an N-terminal bilobal kinase domain and a C-terminal regulatory segment containing two coiled-coils; the first coiled-coil forms a leucine-zipper that mediates homodimerisation and trans-autophosphorylation (fry2002thenek2protein pages 1-3).  
- Crystal structures show the canonical Lys-Glu salt bridge, HRD catalytic triad, DFG motif and an activation loop phosphorylated at Thr175/Thr179 that stabilises the active conformation (rellos2007structureandregulation pages 10-11, fry2017mitoticregulationby pages 6-8).  
- Possesses a non-conserved Cys22 in the Gly-rich loop exploited by reversible covalent inhibitors (dana2022nek2kinasesignaling pages 26-28).  
- Unphosphorylated NEK2 adopts a DFG-out inactive state in complexes with aminopyrazine and benzimidazole inhibitors, illustrating activation-loop plasticity (byrne2020nek7conformationalflexibility pages 14-14).  

## Regulation  
Post-translational modifications  
- Activating autophosphorylation at Thr170/Ser171 and Thr175; Thr179 and Ser241 reduce activity (fang2016targetingnek2as pages 1-2, rellos2007structureandregulation pages 10-11).  
- Interphase complex with PP1 and MST2 keeps NEK2 inactive; Plk1 phosphorylation of MST2 at mitotic onset releases PP1, enabling NEK2 activation (dana2022nek2kinasesignaling pages 2-4).  
- CDK1 and Plk1 add further activating phosphorylations in G2/M (fry2017mitoticregulationby pages 6-8).  
- PP1 dephosphorylates and inhibits NEK2; ATM activation enhances PP1 after DNA damage, down-regulating NEK2 (dana2022nek2kinasesignaling pages 6-7).  
- APC/C targets KEN- and D-box motifs in NEK2A for ubiquitin-dependent degradation at mitotic exit (fang2016targetingnek2as pages 1-2, dana2022nek2kinasesignaling pages 7-9).  

Allosteric and signalling inputs  
- EGFR–PI3K–Akt signalling promotes NEK2 activity via MST2 phosphorylation (fry2017mitoticregulationby pages 4-5).  
- CIP2A binds NEK2 and augments its activity independently of PP1 (dana2022nek2kinasesignaling pages 2-4).  

Transcriptional control  
- FoxM1 up-regulates NEK2, whereas E2F4, p53 and microRNA-128 repress expression, yielding S/G2 phase accumulation (fang2016targetingnek2as pages 1-2).  

## Function  
- Localises to centrosomes and kinetochores; expression peaks in late S/G2 (dana2022nek2kinasesignaling pages 1-2, fry2002thenek2protein pages 1-3).  
- Drives centrosome separation by phosphorylating CEP250, CROCC, CEP68 and related linker proteins (dana2022nek2kinasesignaling pages 2-4, dana2022nek2kinasesignaling pages 28-29).  
- Stabilises kinetochore–microtubule attachments through NDC80 phosphorylation and modulates the spindle-assembly checkpoint via CDC20 and MAD2L1 (dana2022nek2kinasesignaling pages 13-14, dana2022nek2kinasesignaling pages 28-29).  
- Prevents premature centrosome separation after DNA damage, a process reversed by ATM-PP1 signalling (dana2022nek2kinasesignaling pages 2-4, dana2022nek2kinasesignaling pages 6-7).  
- Links to signalling pathways: PP1 Thr320 phosphorylation connects NEK2 to Akt, β-catenin/Dishevelled phosphorylation integrates NEK2 with Wnt signalling, and MST2 interaction places NEK2 within the Hippo network (dana2022nek2kinasesignaling pages 6-7, dana2022nek2kinasesignaling pages 7-9, fry2017mitoticregulationby pages 4-5).  
- Promotes osteoclast differentiation and bone resorption through heparanase up-regulation (dana2022nek2kinasesignaling pages 6-7).  

## Inhibitors  
- ATP-competitive indolinone SU11652 and related purine analogues resolved in NEK2 crystal complexes (fry2017mitoticregulationby pages 6-8).  
- Aminopyrazine and benzimidazole scaffolds stabilising a DFG-out inactive conformation (byrne2020nek7conformationalflexibility pages 14-14).  
- Reversible covalent inhibitors targeting Cys22 (dana2022nek2kinasesignaling pages 26-28).  
- Hec1/NEK2 disruptor T-1101 tosylate with improved oral exposure (dana2022nek2kinasesignaling pages 26-28).  
- PROTAC degraders and activity-based probes are under development for selective NEK2 ablation (dana2022nek2kinasesignaling pages 26-28).  

## Other Comments  
- NEK2 is over-expressed in breast, ovarian, colon, uterine endometrial and lung adenocarcinomas, correlating with aneuploidy, tumour aggressiveness and chemotherapy resistance (dana2022nek2kinasesignaling pages 1-2, dana2022nek2kinasesignaling pages 13-14).  
- Dysregulated NEK2 signalling is also implicated in bone disorders, ciliopathies, immune and kidney diseases, and NEK2 orthologs in Plasmodium spp. are emerging anti-malarial targets (dana2022nek2kinasesignaling pages 1-2, dana2022nek2kinasesignaling pages 13-14).

References

1. (dana2022nek2kinasesignaling pages 1-2): Dibyendu Dana, Tuhin Das, Athena Choi, Ashif I. Bhuiyan, Tirtha K. Das, Tanaji T. Talele, and Sanjai K. Pathak. Nek2 kinase signaling in malaria, bone, immune and kidney disorders to metastatic cancers and drug resistance: progress on nek2 inhibitor development. Molecules, 27:347, Jan 2022. URL: https://doi.org/10.3390/molecules27020347, doi:10.3390/molecules27020347. This article has 14 citations and is from a peer-reviewed journal.

2. (dana2022nek2kinasesignaling pages 13-14): Dibyendu Dana, Tuhin Das, Athena Choi, Ashif I. Bhuiyan, Tirtha K. Das, Tanaji T. Talele, and Sanjai K. Pathak. Nek2 kinase signaling in malaria, bone, immune and kidney disorders to metastatic cancers and drug resistance: progress on nek2 inhibitor development. Molecules, 27:347, Jan 2022. URL: https://doi.org/10.3390/molecules27020347, doi:10.3390/molecules27020347. This article has 14 citations and is from a peer-reviewed journal.

3. (dana2022nek2kinasesignaling pages 2-4): Dibyendu Dana, Tuhin Das, Athena Choi, Ashif I. Bhuiyan, Tirtha K. Das, Tanaji T. Talele, and Sanjai K. Pathak. Nek2 kinase signaling in malaria, bone, immune and kidney disorders to metastatic cancers and drug resistance: progress on nek2 inhibitor development. Molecules, 27:347, Jan 2022. URL: https://doi.org/10.3390/molecules27020347, doi:10.3390/molecules27020347. This article has 14 citations and is from a peer-reviewed journal.

4. (dana2022nek2kinasesignaling pages 26-28): Dibyendu Dana, Tuhin Das, Athena Choi, Ashif I. Bhuiyan, Tirtha K. Das, Tanaji T. Talele, and Sanjai K. Pathak. Nek2 kinase signaling in malaria, bone, immune and kidney disorders to metastatic cancers and drug resistance: progress on nek2 inhibitor development. Molecules, 27:347, Jan 2022. URL: https://doi.org/10.3390/molecules27020347, doi:10.3390/molecules27020347. This article has 14 citations and is from a peer-reviewed journal.

5. (dana2022nek2kinasesignaling pages 28-29): Dibyendu Dana, Tuhin Das, Athena Choi, Ashif I. Bhuiyan, Tirtha K. Das, Tanaji T. Talele, and Sanjai K. Pathak. Nek2 kinase signaling in malaria, bone, immune and kidney disorders to metastatic cancers and drug resistance: progress on nek2 inhibitor development. Molecules, 27:347, Jan 2022. URL: https://doi.org/10.3390/molecules27020347, doi:10.3390/molecules27020347. This article has 14 citations and is from a peer-reviewed journal.

6. (dana2022nek2kinasesignaling pages 6-7): Dibyendu Dana, Tuhin Das, Athena Choi, Ashif I. Bhuiyan, Tirtha K. Das, Tanaji T. Talele, and Sanjai K. Pathak. Nek2 kinase signaling in malaria, bone, immune and kidney disorders to metastatic cancers and drug resistance: progress on nek2 inhibitor development. Molecules, 27:347, Jan 2022. URL: https://doi.org/10.3390/molecules27020347, doi:10.3390/molecules27020347. This article has 14 citations and is from a peer-reviewed journal.

7. (dana2022nek2kinasesignaling pages 7-9): Dibyendu Dana, Tuhin Das, Athena Choi, Ashif I. Bhuiyan, Tirtha K. Das, Tanaji T. Talele, and Sanjai K. Pathak. Nek2 kinase signaling in malaria, bone, immune and kidney disorders to metastatic cancers and drug resistance: progress on nek2 inhibitor development. Molecules, 27:347, Jan 2022. URL: https://doi.org/10.3390/molecules27020347, doi:10.3390/molecules27020347. This article has 14 citations and is from a peer-reviewed journal.

8. (fry2002thenek2protein pages 1-3): A. Fry. The nek2 protein kinase: a novel regulator of centrosome structure. Oncogene, 21:6184-6194, Sep 2002. URL: https://doi.org/10.1038/sj.onc.1205711, doi:10.1038/sj.onc.1205711. This article has 277 citations and is from a domain leading peer-reviewed journal.

9. (fry2017mitoticregulationby pages 6-8): Andrew M. Fry, Richard Bayliss, and Joan Roig. Mitotic regulation by nek kinase networks. Frontiers in Cell and Developmental Biology, Dec 2017. URL: https://doi.org/10.3389/fcell.2017.00102, doi:10.3389/fcell.2017.00102. This article has 105 citations and is from a peer-reviewed journal.

10. (fang2016targetingnek2as pages 1-2): Yan-fen Fang and Xiongwen Zhang. Targeting nek2 as a promising therapeutic approach for cancer treatment. Cell Cycle, 15:895-907, Mar 2016. URL: https://doi.org/10.1080/15384101.2016.1152430, doi:10.1080/15384101.2016.1152430. This article has 149 citations and is from a peer-reviewed journal.

11. (fry2017mitoticregulationby pages 1-2): Andrew M. Fry, Richard Bayliss, and Joan Roig. Mitotic regulation by nek kinase networks. Frontiers in Cell and Developmental Biology, Dec 2017. URL: https://doi.org/10.3389/fcell.2017.00102, doi:10.3389/fcell.2017.00102. This article has 105 citations and is from a peer-reviewed journal.

12. (fry2017mitoticregulationby pages 4-5): Andrew M. Fry, Richard Bayliss, and Joan Roig. Mitotic regulation by nek kinase networks. Frontiers in Cell and Developmental Biology, Dec 2017. URL: https://doi.org/10.3389/fcell.2017.00102, doi:10.3389/fcell.2017.00102. This article has 105 citations and is from a peer-reviewed journal.

13. (rellos2007structureandregulation pages 10-11): P. Rellos, Frank J. Ivins, Joanne E. Baxter, A. Pike, T. J. Nott, D. Parkinson, Sanjan K. Das, S. Howell, O. Fedorov, Q. Shen, A. Fry, S. Knapp, and S. Smerdon. Structure and regulation of the human nek2 centrosomal kinase*. Journal of Biological Chemistry, 282:6833-6842, Mar 2007. URL: https://doi.org/10.1074/jbc.m609721200, doi:10.1074/jbc.m609721200. This article has 155 citations and is from a domain leading peer-reviewed journal.

14. (byrne2020nek7conformationalflexibility pages 14-14): M. Byrne, N. Nasir, C. Basmadjian, C. Bhatia, R. Cunnison, K. Carr, C. Mas-Droux, S. Yeoh, Céline Cano, and R. Bayliss. Nek7 conformational flexibility and inhibitor binding probed through protein engineering of the r-spine. Biochemical Journal, 477:1525-1539, Apr 2020. URL: https://doi.org/10.1042/bcj20200128, doi:10.1042/bcj20200128. This article has 15 citations and is from a domain leading peer-reviewed journal.
